Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COM503 · 1 trial · 2 indications
Number of participants in monotherapy cohorts with treatment-related adverse events as assessed by CTCAE v4.0
Number of participants in combination cohorts with treatment-related adverse events as assessed by CTCAE v4.
| Arm | Type | Description |
|---|---|---|
| Part 1, A-1 | EXPERIMENTAL | Monotherapy Dose Escalation |
| Part 1, A-2 | EXPERIMENTAL | Backfill |
| Part 1, B | EXPERIMENTAL | Dose escalation, COM503 in combination with a fixed dose of zimberelimab. |
| Part 2, A | EXPERIMENTAL | Dose expansion, COM503 monotherapy |
| Part 2, B | EXPERIMENTAL | Dose expansion, COM503 in combination with a fixed dose of zimberelimab. |
| Name | Type | Description |
|---|---|---|
| COM503 | DRUG | Intravenous Infusion |
| Zimberelimab | DRUG | Intravenous infusion |
Inclusion Criteria: * Participants with histologically/cytologically confirmed advanced recurrent or metastatic solid tumor malignancy * Part 1 (dose escalation): Participants must have had disease progression on or following all available standard of care (SOC) therapies known to confer clinical b...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
COM503 is an investigational small molecule being developed for the treatment of neoplasms, including advanced solid malignancies. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
COM503 targets IL-18, a binding protein involved in immune signaling. By modulating IL-18 activity, the drug aims to affect the tumor microenvironment in oncology indications. The specific mechanism of action is under investigation in clinical trials.
COM503 is being developed by Compugen Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol CGEN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
COM503 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The ongoing Phase 1 trial is recruiting participants to assess the drug in advanced solid malignancies.
COM503 is being evaluated in a Phase 1 clinical trial with the identifier NCT06759649. This trial is recruiting approximately 200 participants with advanced solid malignancies in the United States and Israel. The study is open to adults aged 18 years and older.
COM503 is a distinct investigational drug developed by Compugen Ltd. It is not known to be the same as any other approved or investigational medication. Its unique target, IL-18 binding protein, differentiates it from other oncology therapies.